These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1267 related articles for article (PubMed ID: 16968952)

  • 1. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.
    Chou TC
    Pharmacol Rev; 2006 Sep; 58(3):621-81. PubMed ID: 16968952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug combination studies and their synergy quantification using the Chou-Talalay method.
    Chou TC
    Cancer Res; 2010 Jan; 70(2):440-6. PubMed ID: 20068163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical versus clinical drug combination studies.
    Chou TC
    Leuk Lymphoma; 2008 Nov; 49(11):2059-80. PubMed ID: 19021049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mass-action law based algorithms for quantitative econo-green bio-research.
    Chou TC
    Integr Biol (Camb); 2011 May; 3(5):548-59. PubMed ID: 21403972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development.
    Chou TC
    Am J Cancer Res; 2011; 1(7):925-54. PubMed ID: 22016837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method.
    Zhang N; Fu JN; Chou TC
    Am J Cancer Res; 2016; 6(1):97-104. PubMed ID: 27073727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
    Chou TC; Motzer RJ; Tong Y; Bosl GJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of cooperativity on the determination of dissociation constants: examination of the Cheng-Prusoff equation, the Scatchard analysis, the Schild analysis and related power equations.
    Cheng HC
    Pharmacol Res; 2004 Jul; 50(1):21-40. PubMed ID: 15082026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational approach to the clinical protocol design for drug combinations: a review.
    Chang TT; Chou TC
    Acta Paediatr Taiwan; 2000; 41(6):294-302. PubMed ID: 11198934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.
    Chou TC; Talalay P
    Adv Enzyme Regul; 1984; 22():27-55. PubMed ID: 6382953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental designs for detecting synergy and antagonism between two drugs in a pre-clinical study.
    Sperrin M; Thygesen H; Su TL; Harbron C; Whitehead A
    Pharm Stat; 2015; 14(3):216-25. PubMed ID: 25810342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CombiTool--a new computer program for analyzing combination experiments with biologically active agents.
    Dressler V; Müller G; Sühnel J
    Comput Biomed Res; 1999 Apr; 32(2):145-60. PubMed ID: 10337496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the combination index (CI)-isobologram equation to study the toxicological interactions of lipid regulators in two aquatic bioluminescent organisms.
    Rodea-Palomares I; Petre AL; Boltes K; Leganés F; Perdigón-Melón JA; Rosal R; Fernández-Piñas F
    Water Res; 2010 Jan; 44(2):427-38. PubMed ID: 19683324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A flexible unified approach to the analysis of pre-clinical combination studies.
    Harbron C
    Stat Med; 2010 Jul; 29(16):1746-56. PubMed ID: 20572122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple drug effect analysis with confidence interval.
    Belen'kii MS; Schinazi RF
    Antiviral Res; 1994 Sep; 25(1):1-11. PubMed ID: 7811057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of drug interactions.
    Bijnsdorp IV; Giovannetti E; Peters GJ
    Methods Mol Biol; 2011; 731():421-34. PubMed ID: 21516426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico synergism and antagonism of an anti-tumour system intervened by coupling immunotherapy and chemotherapy: a mathematical modelling approach.
    Hu WY; Zhong WR; Wang FH; Li L; Shao YZ
    Bull Math Biol; 2012 Feb; 74(2):434-52. PubMed ID: 21972030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Communicating synergism in drug combination studies.
    Brodkin J; Shannon HE
    Arzneimittelforschung; 2000 Aug; 50(8):765-7. PubMed ID: 10994162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study.
    Boik JC; Newman RA; Boik RJ
    Stat Med; 2008 Mar; 27(7):1040-61. PubMed ID: 17768754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental design and statistical analysis for three-drug combination studies.
    Fang HB; Chen X; Pei XY; Grant S; Tan M
    Stat Methods Med Res; 2017 Jun; 26(3):1261-1280. PubMed ID: 25744107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.